Serum LTBP-2 levels detected heart failure with reduced ejection fraction with an AUC of 0.67 (95% CI 0.58-0.75), comparable to NT-proBNP (AUC 0.68).
Cohort (n=133)
Does serum LTBP-2 level act as a diagnostic biomarker for HFrEF in patients with dyspnea?
Serum LTBP-2 levels show comparable diagnostic ability to NT-proBNP for detecting HFrEF in patients presenting with dyspnea.
Effect estimate: AUC 0.67 (95% CI 0.58-0.75)
Absolute Event Rate: 0.67% vs 0.68%
BACKGROUND: We have observed increased expression of latent TGF-β binding protein (LTBP)-2 mRNA in human failing hearts. This study was aimed to further confirm LTBP-2 act as a novel marker in human acute heart failure. METHODS AND RESULTS: We demonstrated that median level of LTBP-2 in myocardial samples from heart failure patients was significantly elevated, and TGF-β1 significantly promoted LTBP-2 expression in neonatal rat cardiomyocytes. To investigate the potential of LTBP-2 as a biomarker to diagnose heart failure with reduced ejection fraction (HFREF), another cohort of 133 consecutive patients with dyspnea were enrolled. In receiver operating characteristic (ROC) curve analyses to detect HFREF, LTBP-2 achieved an area under curve (AUC) of 0.67 (95% confidence intervals (CI) 0.58-0.75), comparable to the diagnostic ability of NT-proBNP 0.68 (95% CI 0.59-0.77). CONCLUSION: The serum LTBP-2 levels might act as a promising biomarker in HFREF.
Bai et al. (Thu,) conducted a cohort in Heart failure with reduced ejection fraction (HFREF) (n=133). LTBP-2 vs. NT-proBNP was evaluated on Detection of HFREF (AUC 0.67, 95% CI 0.58-0.75). Serum LTBP-2 levels detected heart failure with reduced ejection fraction with an AUC of 0.67 (95% CI 0.58-0.75), comparable to NT-proBNP (AUC 0.68).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: